标题：乳腺癌患者E-钙黏附蛋白、肌切蛋白的表达水平与新辅助化疗疗效的相关性

      作者：魏鹏 1，陈鹏 2    1.陕西省核工业二一五医院普外一科，陕西 咸阳 712000；2.三原县医院普外二科，陕西 咸阳 713800

      卷次： 2022年33卷7期

      【摘要】 目的 研究乳腺癌患者E-钙黏附蛋白、肌切蛋白的表达水平与新辅助化疗效果的关系。方法 选取2017年4月至2020年4月陕西省核工业二一五医院收治的78例乳腺癌患者为研究对象，所有患者均接受新辅助化疗结合手术治疗，持续化疗4个周期，于化疗结束后评价临床疗效，根据评价效果将临床完全缓解、病理完全缓解、临床部分缓解患者纳入疗效较好组(n=51)，临床稳定、临床进展者纳入疗效较差组(n=27)。比较两组患者的临床特征以及治疗前后的E-钙黏附蛋白、肌切蛋白水平和E-钙黏附蛋白、肌切蛋白阳性表达率；E-钙黏附蛋白、肌切蛋白与新辅助化疗疗效的相关性采用Pearson相关分析。结果 疗效较差组患者的淋巴结转移率为88.88%，远高于疗效较好组的11.76%，差异具有统计学意义(P<0.05)；治疗后，疗效较差组患者的E-钙黏附蛋白和肌切蛋白平均积分光密度值分别为(25.58±5.13)%和(21.42±5.21)%，明显高于疗效较好组的(21.01±5.15)%和(15.98±5.18)%，差异均具有统计学意义(P<0.05)；疗效较差组患者的E-钙黏附蛋白和肌切蛋白阳性率分别为92.59%、96.29%，明显高于疗效较好组的 47.05%、43.13%，差异均具有统计学意义 (P<0.05)；经 Pearson相关性分析结果显示，E-钙黏附蛋白(r=-0.095，P<0.01)、肌切蛋白(r=-4.27，P=0.031)表达与新辅助化疗疗效均呈负相关。结论 乳腺癌患者体内E-钙黏附蛋白、肌切蛋白参与了乳腺癌的发展，且E-钙黏附蛋白、肌切蛋白与新辅助化疗疗效均呈负相关。
      【关键词】 乳腺癌；E-钙黏附蛋白；肌切蛋白；表达；新辅助化疗；相关性
      【中图分类号】 R737.9 【文献标识码】 A 【文章编号】 1003—6350（2022）07—0853—04

Correlation between the expression of E-cadherin and scinderin in breast cancer patients and the effect ofneoadjuvant chemotherapy.
WEI Peng 1, CHEN Peng 2.1. First Division of General Surgery, NO.215 Hospital of ShaanxiNuclear Industry, Xianyang 712000, Shaanxi, CHINA; 2. Second Division of General Surgery, Sanyuan County Hospital,Xianyang 713800, Shaanxi, CHINA
【Abstract】 Objective To study the relationship between the expression of E-cadherin and scinderin in breastcancer patients and the effect of neoadjuvant chemotherapy. Methods A total of 78 breast cancer patients admitted toNo.215 Hospital of Shaanxi Nuclear Industry from April 2017 to April 2020 were selected as the research objects. All pa-tients received neoadjuvant chemotherapy combined with surgical treatment and continued chemotherapy for 4 courses.After chemotherapy, the clinical efficacy was evaluated. According to the evaluation results, patients with complete clini-cal remission, complete pathological remission, and partial clinical remission were included in the better efficacy group(n=51), and those with clinical stability and clinical progress were included in the poor efficacy group (n=27). The clini-cal characteristics of the two groups were compared, as well as the serum levels and the positive expression rates ofE-cadherin and scinderin before and after treatment. The correlation between E-cadherin, scinderin and the efficacy of